The JenaValve ALIGN-AR Pivotal Trial (ALIGN-AR)

Investigator: Michael Reardon, MD

Study Coordinator: Yejide Oyewole

Status: Enrolling Number: NCT04415047

Phone: 346.238.2294

Protocol Number: PRO00028310


Brief Summary: To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery. Detailed Description: This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat symptomatic severe aortic regurgitation. Inclusion Criteria: Patient with severe aortic regurgitation (AR). Patient at high risk for open surgical valve replacement Patient symptomatic according to NYHA functional class II or higher The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site. Exclusion Criteria: Congenital uni or bicuspid aortic valve morphology Previous prosthetic aortic valve (bioprosthesis or mechanical) implant Endocarditis or other active infection Need for urgent or emergent TAVR procedure for any reason Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device Severe mitral regurgitation
More to Explore